Uliginosin B, a Possible New Analgesic Drug, Acts by Modulating the Adenosinergic System

Abstract EN

Uliginosin B (ULI) is a natural acylphloroglucinol that has been proposed as a new molecular scaffold for developing analgesic and antidepressant drugs.

Its effects seem to be due to its ability to increase monoamines in the synaptic cleft by inhibiting their neuronal uptake without binding to their respective transporters, but its exact mode of action is still unknown.

Considering the importance of the purinergic system to pain transmission and its modulation by monoamines availability, the aim of this study was to investigate the involvement of adenosinergic signaling in antinociceptive effect of uliginosin B.

The selective adenosine A1 receptor antagonist DPCPX and the selective A 2 A antagonist ZM 241385 prevented the effect of ULI in the hot-plate test in mice.

Pretreatment with inhibitors of adenosine reuptake (dipyridamole) or adenosine deaminase (EHNA) did not affect the ULI effect.

On the other hand, its effect was completely prevented by an inhibitor of ecto-5′-nucleotidase (AMPCP).

This finding was confirmed ex vivo, whereby ULI treatment increased AMP and ATP hydrolysis in spinal cord and cerebral cortex synaptosomes, respectively.

Altogether, these data indicate that activation of A1 and A 2 A receptors and the modulation of ecto-5′-nucleotidase activity contribute to the antinociceptive effect of ULI.